Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1Bezafibrate[1] Bezafibrate (Bezafibrate)[1] Bezafibrate (Bezafibrate) 💬 [1] NR1C1 💬 [10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬[8] 20, 93, 94, 160, 296, 316, 324, 344 💬
2Bezafibrate (400MG) IN addition TO standard 15-20 MG/KG/jour udca therapy[2] Bezafibrate (Bezafibrate),
Ursodeoxycholic acid		[2] Ursodiol ,
Bezafibrate (Bezafibrate) 💬 		[2] NR1C1,
NR1H4 💬 		[11] Adipocytokine signaling pathway, Alcoholic liver disease, Bile secretion, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬[1] 94 💬
3Bezafibrate 100 MG[1] Bezafibrate (Bezafibrate)[1] Bezafibrate (Bezafibrate) 💬 [1] NR1C1 💬 [10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬[1] 93 💬
4Bezafibrate 200 MG[1] Bezafibrate (Bezafibrate)[1] Bezafibrate (Bezafibrate) 💬 [1] NR1C1 💬 [10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬[1] 93 💬
5Bezafibrate 200 MG IN addition TO udca therapy[2] Bezafibrate (Bezafibrate),
Ursodeoxycholic acid		[2] Ursodiol ,
Bezafibrate (Bezafibrate) 💬 		[2] NR1C1,
NR1H4 💬 		[11] Adipocytokine signaling pathway, Alcoholic liver disease, Bile secretion, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬[1] 93 💬
6Bezafibrate 200 MG oral tablet[1] Bezafibrate (Bezafibrate)[1] Bezafibrate (Bezafibrate) 💬 [1] NR1C1 💬 [10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬[1] 93 💬
7Bezafibrate 400 MG[1] Bezafibrate (Bezafibrate)[1] Bezafibrate (Bezafibrate) 💬 [1] NR1C1 💬 [10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬[1] 93 💬
8Bezafibrate 400 MG IN addition TO udca therapy[2] Bezafibrate (Bezafibrate),
Ursodeoxycholic acid		[2] Ursodiol ,
Bezafibrate (Bezafibrate) 💬 		[2] NR1C1,
NR1H4 💬 		[11] Adipocytokine signaling pathway, Alcoholic liver disease, Bile secretion, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬[1] 93 💬
9Bezafibrate IR[1] Bezafibrate (Bezafibrate)[1] Bezafibrate (Bezafibrate) 💬 [1] NR1C1 💬 [10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬[1] 93 💬
10Bezafibrate SR[1] Bezafibrate (Bezafibrate)[1] Bezafibrate (Bezafibrate) 💬 [1] NR1C1 💬 [10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬[1] 93 💬
11Bezafibrate, beza, BZF, bezalip[1] Bezafibrate (Bezafibrate)[1] Bezafibrate (Bezafibrate) 💬 [1] NR1C1 💬 [10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬[1] 93 💬
12Bezafibrate, beza, BZF, bezalip mono[1] Bezafibrate (Bezafibrate)[1] Bezafibrate (Bezafibrate) 💬 [1] NR1C1 💬 [10] Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬[1] 93 💬